A Phase 1 interventional study of Crovalimab and Placebo in Sickle Cell Disease, sponsored by Hoffmann-La Roche. Completed at 16 sites in 10 countries. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Anemia, Sickle Cell with a site in Spain — 8 open to participants now, 12 under way, 5 of them phase 3. Anemia, Sickle Cell · Spain.
Among the 23 studies in Anemia, Sickle Cell with a site in Spain, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 1, and was the 11th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 23 studies in Anemia, Sickle Cell with a site in Spain are open now. Recruiting first, the newest first:
Sanofi · Sites in Spain, United States, Belgium and 11 more countries
Ages 10–65
Novo Nordisk A/S · Sites in Spain, United States, Australia and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in Spain, United States, Canada and 14 more countries
Ages 2+
Cyprus Institute of Neurology and Genetics · Sites in Spain, United States, Angola and 13 more countries
Ages 2+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages up to 100
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 161 across the 16 interventional studies, 1,500 across the 7 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 23 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia, Sickle Cell with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06975865Phase 3SanofiThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | 2027-07-23 |
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT06794281Hospital Universitari Vall d'Hebron Research InstituteSynthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case | 2026-11-30 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Anemia, Sickle Cell with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD. The primary objective of this study is safety and will additionally evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
Drug: Crovalimab
Participants will receive a single IV infusion of matching Placebo.
Drug: Placebo
Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
Percentage of Participants With Adverse Events (AEs)
Time frame: Baseline up to Day 84
Percentage of Participants with Infusion-Related Reactions and Hypersensitivity
Time frame: Baseline up to Day 84
Time to Improvement of the Primary Acute Uncomplicated VOE From Baseline
Time frame: Baseline up to Day 84
Total Cumulative Opioid Dose From Baseline
Time frame: Baseline up to Day 84
Time to Discontinuation of all Parenteral Opioids From Baseline
Time frame: Baseline up to Day 84
Time to Readiness For Hospital Discharge From Baseline
Time frame: Baseline up to Day 84
Time to Hospital Discharge From Baseline
Time frame: Baseline up to Day 84
Time to a Confirmed Decrease in Pain Score of at Least 2 Points From the Maximal Pre-dose Pain Score
Time frame: Baseline up to Day 84
Change in Pain Score From the Maximal Pre-dose Pain Score to the Score at Hospital Discharge
Time frame: Baseline up to Day 84
Percentage of Participants who Develop Acute Chest Syndrome (ACS)
Time frame: Baseline up to Day 28
Percentage of Participants Requiring Intensive Care Unit (ICU)/Critical Care Admission for SCD-related Complications
Time frame: Baseline up to Day 84
Percentage of Participants Requiring Blood Transfusion for SCD-related Complications
Time frame: Baseline up to Day 84
Readmission Rate for a VOE or VOE-related Event Within 28 days of Discharge of the Primary Acute Uncomplicated VOE
Time frame: Baseline up to Day 84
Serum Concentrations of Crovalimab Over Time
Time frame: Baseline up to Day 84
Change in PD Biomarkers Including Complement Activity (CH50) Over Time
Assessed by a Liposome Immunoassay (LIA)
Time frame: Baseline up to Day 84
Change Over Time in Free C5 Concentration
Time frame: Baseline up to Day 84
Change Over Time in Soluble Complement 5b 9 (sC5b-9) Concentration
Time frame: Baseline up to Day 84
Percentage of Participants with Anti-Drug Antibodies to Crovalimab
Time frame: Baseline up to Day 84
Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Dec 2024, 32 months.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 32 months is above that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crovalimab